Wells Fargo & Company Uro Gen Pharma Ltd. Call Options Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding URGN
# of Institutions
154Shares Held
38.4MCall Options Held
1.93MPut Options Held
594K-
Rtw Investments, LP New York, NY4.54MShares$87.2 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$61.3 Million0.08% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$42.2 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$42.1 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.19MShares$42 Million2.32% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $437M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...